×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Coronavirus | Financial Markets | Money | Vaccines | Food and Drug Administration | COVID-19 vaccination | Merck

FDA to Review Merck's COVID-19 Vaxx: Bloomberg

Merck
(AP)

Thursday, 14 October 2021 01:06 PM

The U.S. Food and Drug Administration will send drugmaker Merck & Co's experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.

The advisory committee will weigh in on molnupiravir's safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report said.

Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

Merck, Pfizer, Roche -- All in Race for a Pill

Pfizer Inc and Swiss drugmaker Roche Holding AG are also racing to develop an easy-to-administer antiviral pill for COVID-19.

Merck is developing molnupiravir in partnership with U.S.-based Ridgeback Biotherapeutics.

In early October, data showed Merck's drug could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19, pummeling shares of coronavirus vaccine makers.

The FDA and Merck did not immediately respond to Reuters' requests for comment.

© 2021 Thomson/Reuters. All rights reserved.


StreetTalk
The U.S. Food and Drug Administration (FDA) will send drug maker Merck & Co.'s experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.
Food and Drug Administration, COVID-19 vaccination, Merck, Pfizer, Roche
186
2021-06-14
Thursday, 14 October 2021 01:06 PM
Newsmax Media, Inc.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved